Member Info for Yorkshirepragma

MM info in public domain . Assuming sales reach reasonable levels in this range then there will be a good contribution to Rev.
GLA

Shared a chat with a young investment banker( who’d moved N ,)on why a share value is recognised , subtly or otherwise.
With Biotech it’s of course on +ve changing news , make your own mind up here!
( expect multiple 10 plus on projected )
GLA

https://www.valuationresearch.com/pure-perspectives/valuation-industry-update-biotechnology/

And VIP ….illustrates new spate of contracts being issued.
Bodes well

Salutary listen, puts all in perspective…

Ref Baroness reply …small possibly of error.. up to 40% with NHS sourced Biotime….ridiculous.

It’s quite an extraordinary situation, and Porton and Sir John Bell will have some explaining to do at some point!

https://www.grandviewresearch.com/industry-analysis/covid-19-diagnostics-market

As a long term holder , AS team does it for me. Biotech notoriously success or failure... in this case the former for sure...
Bio vals .. DYOR
GLA

Sunday evening reading….last large biotech buy Kite..T cell cancer therapy.
Sounds familiar?

https://www.businessinsider.com/gilead-to-buy-kite-pharma-for-12-billion-a-cancer-immunotherapy-company-2017-8?r=US&IR=T

https://gb.bebee.com/job/20210818-106671438f57ab2ed62f48d876123d4f?utm_campaign=google_jobs_apply&utm_source=google_jobs_apply&utm_medium=organic

Wonder why??

£54/94 m . Now that’s indicative of where the actions at.

Buys sig.> sells.
Global markets affected by China business fall back jitters from covid outbreaks ,testing value?
Etc
GLA

Takeover odds within 2 years?
GLA

&re21..takeover... odds shortening in the small world if pharma...
GLA

Correct

No 2 daughter at client meet today , tested on entry ( easy nasal swab only) with ... ! Impressive and easy
GLA

https://www.worldometers.info/coronavirus/

Sadly a lot of tests needed.

& ‘best in class’ , now let’s see…..what’s likely to Occur?
GLA

We’re now in the ‘ consolidation’ period for purchases, where quality and efficacy will be the key factor. Some litigious issues inevitably around use will drive only the best to survive.
GLA